Essential Pharma Acquires Renaissance Pharma Ltd
April 2, 2024
Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.
- Buyers
- Essential Pharma
- Targets
- Renaissance Pharma Ltd
- Industry
- Pharmaceuticals
- Location
- Greater Manchester, United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.